Evidence map›Paper›PMID 27528026›Full record

ArticleOncotarget2016

The gain and loss of long noncoding RNA associated-competing endogenous RNAs in prostate cancer.

Dianming Liu, Xuexin Yu, Shuyuan Wang, Enyu Dai, Leiming Jiang, Jing Wang, Qian Yang, Feng Yang, Shunheng Zhou, Wei Jiang

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
4.3field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 48 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Regulatory role of long non-coding RNAs during reproductive disease.American journal of translational research · 2018
    Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Dianming LiuCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin 150081, China.
Xuexin YuCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin 150081, China.
Shuyuan WangCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin 150081, China.
Enyu DaiCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin 150081, China.
Leiming JiangCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin 150081, China.
Jing WangCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin 150081, China.
Qian YangCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin 150081, China.
Feng YangCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin 150081, China.
Shunheng ZhouCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin 150081, China.
Wei JiangCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin 150081, China.
Harbin Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Prostate cancer (PC) is one of the most common solid tumors in men. However, the molecular mechanism of PC remains unclear. Numerous studies have demonstrated that long noncoding RNA (lncRNA) can act as microRNA (miRNA) sponge, one type of competing endogenous RNAs (ceRNAs), which offers a novel viewpoint to elucidate the mechanisms of PC. Here, we proposed an integrative systems biology approach to infer the gain and loss of ceRNAs in PC. First, we re-annotated exon microarray data to obtain lncRNA expression profiles of PC. Second, by integrating mRNA and miRNA expression, as well as miRNA targets, we constructed lncRNA-miRNA-mRNA ceRNA networks in cancer and normal samples. The lncRNAs in these two ceRNA networks tended to have a longer transcript length and cover more exons than the lncRNAs not involved in ceRNA networks. Next, we further extracted the gain and loss ceRNA networks in PC. We found that the gain ceRNAs in PC participated in cell cycle, and the loss ceRNAs in PC were associated with metabolism. We also identified potential prognostic ceRNA pairs such as MALAT1-EGR2 and MEG3-AQP3. Finally, we inferred a novel mechanism of known drugs, such as cisplatin, for the treatment of PC through gain and loss ceRNA networks. The potential drugs such as 1,2,6-tri-O-galloyl-beta-D-glucopyranose (TGGP) could modulate lncRNA-mRNA competing relationships, which may uncover new strategy for treating PC. In summary, we systematically investigated the gain and loss of ceRNAs in PC, which may prove useful for identifying potential biomarkers and therapeutics for PC.

Indexed as

Gene Expression Regulation, NeoplasticAquaporin 3Early Growth Response Protein 2ExonsGene Expression ProfilingGene Regulatory NetworksHumansHydrolyzable TanninsMaleMicroRNAsOligonucleotide Array Sequence AnalysisPrognosisProstatic NeoplasmsRNA, Long NoncodingRNA, MessengerSystems Biology1,2,6-tri-O-galloyl-beta-D-glucopyranoseAQP3 protein, humanAquaporin 3Early Growth Response Protein 2EGR2 protein, humanHydrolyzable TanninsMALAT1 long non-coding RNA, humanMEG3 non-coding RNA, humanMicroRNAsRNA, Long NoncodingRNA, MessengerceRNAlncRNAmiRNAmiRNA spongeprostate cancer

Identifiers

PMID27528026
PMCPMC5302985
OpenAlexW2512464307

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.